ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025
Atopy Improves Survival and Decreases Risk of Brain Metastasis in Cutaneous Melanoma.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
12 authors.
Funding
Abstract
backgroundDevelopment of new melanoma therapies has increased survival, and more patients are living to develop brain metastasis (BrM). Identifying those at increased risk of BrM is of significant public health importance, and our objective was to assess the relationship between atopy and survival or reduced BrM cumulative incidence (CI) in melanoma.
methodsThis retrospective study was conducted in individuals (≥66 years) in linked Surveillance, Epidemiology, and End Results and Medicare data. History of atopy diagnosed prior to melanoma was ascertained using International Classification of Diseases-9/10 codes. Associations between atopy, CI of BrM, and overall survival were assessed using cox proportional hazards models to estimate hazard ratios and P values.
resultsA total of 23,508 cutaneous melanoma cases were identified. Overall, 6.1% developed BrM, and 38% had history of atopy. Atopy was associated with an 18% decrease in death (P < 0.001). Among those without metastasis at diagnosis, atopy decreased BrM CI by 16% (P = 0.006). Among those with metastasis at diagnosis (any site), only those who received checkpoint inhibitors had a suggestive but nonsignificant survival with atopy.
conclusionsAtopy confers improved survival and decreased BrM CI. History of atopy in the elderly may identify those with more robust immune function that may be more responsive to treatment. IMPACT: Elderly individuals with prior diagnosis of atopy had significantly improved survival and decreased incidence of BrM as compared with individuals without atopy. This suggests that history of atopy may identify a subgroup within melanoma with improved response to treatment and a more robust immune system.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.